Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

10.50
+0.24002.34%
Post-market: 10.500.00000.00%19:30 EDT
Volume:752.20K
Turnover:7.90M
Market Cap:652.67M
PE:-8.41
High:10.72
Open:10.15
Low:10.15
Close:10.26
52wk High:11.15
52wk Low:4.50
Shares:62.16M
Float Shares:55.78M
Volume Ratio:0.91
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.55
PE(LYR):-6.65

Loading ...

Sagimet Biosciences Inc : Canaccord Genuity Raises Target Price to $49 From $28

THOMSON REUTERS
·
May 05

Sagimet Biosciences Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
May 04

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from JonesTrading

TIPRANKS
·
May 04

Oppenheimer Adjusts Price Target on Sagimet Biosciences to $33 From $28, Maintains Outperform Rating

MT Newswires Live
·
May 01

Sagimet Biosciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Apr 30

Sagimet Biosciences price target lowered to $25 from $27 at Guggenheim

TIPRANKS
·
Apr 29

3 Penny Stocks to Watch Now, 4/28/26

TIPRANKS
·
Apr 29

Sagimet Biosciences holds a conference call

TIPRANKS
·
Apr 29

BRIEF-Sagimet Biosciences Offers 29.17 Million Shares Of Series A Common Stock - SEC Filing

Reuters
·
Apr 28

Sagimet Biosciences Inc - Offering 29.17 Mln Shares of Series a Common Stock - SEC Filing

THOMSON REUTERS
·
Apr 28

NASD Most Active Issues

Dow Jones
·
Apr 28

Top Midday Gainers

MT Newswires Live
·
Apr 28

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Benzinga
·
Apr 28

Sagimet Biosciences Shares Rise With Focus on Acne Treatment

Dow Jones
·
Apr 27

Sagimet Highlights Pipeline Progress and Strategic Corporate Developments

TIPRANKS
·
Apr 27

Sagimet Biosciences Inc - Prices 29.2 Mln Series a Common Shares at $6.00 per Share

THOMSON REUTERS
·
Apr 27

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

GlobeNewswire
·
Apr 27

Sagimet plans US Phase 3 denifanstat acne trial start in H2 2026

Reuters
·
Apr 27

Sagimet Biosciences Inc - Plans Phase 3 Trial of Denifanstat in U.S. Acne Patients in H2 2026

THOMSON REUTERS
·
Apr 27

Sagimet Biosciences Provides Strategic and Corporate Updates

GlobeNewswire
·
Apr 27